Evidence map›Paper›PMID 36559201›Full record

ReviewPharmaceutics2022

Could the Lung Be a Gateway for Amphotericin B to Attack the Army of Fungi?

Beatriz Ferreira de Carvalho Patricio, Juliana Oliveira da Silva Lopes Pereira, Michelle Alvares Sarcinelli, Bianca Portugal Tavares de Moraes, Helvécio Vinicius Antunes Rocha, Cassiano Felippe Gonçalves-de-Albuquerque

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Beatriz Ferreira de Carvalho PatricioPharmacology Laboratory, Biomedical Institute, Federal University of State of Rio de Janeiro, 94 Frei Caneca Street, Rio de Janeiro 20211-010, Brazil.ORCID 0000-0002-2477-9798
Juliana Oliveira da Silva Lopes PereiraPharmacology Laboratory, Biomedical Institute, Federal University of State of Rio de Janeiro, 94 Frei Caneca Street, Rio de Janeiro 20211-010, Brazil.
Michelle Alvares SarcinelliLaboratory of Micro and Nanotechnology, Institute of Technology of Drugs, Oswaldo Cruz Foundation, Brazil Av., 4036, Rio de Janeiro 213040-361, Brazil.ORCID 0000-0002-2364-9270
Bianca Portugal Tavares de MoraesPostgraduate Program in Biotechnology, Biology Institute, Federal Fluminense University, Rua Prof. Marcos Waldemar de Freitas Reis, Niterói 24210-201, Brazil.ORCID 0000-0003-1524-2873
Helvécio Vinicius Antunes RochaLaboratory of Micro and Nanotechnology, Institute of Technology of Drugs, Oswaldo Cruz Foundation, Brazil Av., 4036, Rio de Janeiro 213040-361, Brazil.
Cassiano Felippe Gonçalves-de-AlbuquerquePostgraduate Program in Molecular and Cell Biology, Biomedical Institute, Federal University of State of Rio de Janeiro, 94 Frei Caneca Street, Rio de Janeiro 20211-010, Brazil.ORCID 0000-0002-4458-3055
Fundação Oswaldo Cruz · BRUniversidade Federal do Rio de Janeiro · BRUniversidade Federal Fluminense · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fungal diseases are a significant cause of morbidity and mortality worldwide, primarily affecting immunocompromised patients.

Indexed as

amphotericin Bnanoformulationspulmonary drug deliverypulmonary fungal infection

Identifiers

PMID36559201
PMCPMC9784761
OpenAlexW4311521822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.